These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1042 related articles for article (PubMed ID: 26751493)

  • 1. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
    Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
    Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
    Jangampalli Adi P; Reddy PH
    Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
    Navarrete LP; Pérez P; Morales I; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.
    Brunden KR; Ballatore C; Crowe A; Smith AB; Lee VM; Trojanowski JQ
    Exp Neurol; 2010 Jun; 223(2):304-10. PubMed ID: 19744482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tauopathy: A common mechanism for neurodegeneration and brain aging.
    Saha P; Sen N
    Mech Ageing Dev; 2019 Mar; 178():72-79. PubMed ID: 30668956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Degradation or aggregation: the ramifications of post-translational modifications on tau.
    Park S; Lee JH; Jeon JH; Lee MJ
    BMB Rep; 2018 Jun; 51(6):265-273. PubMed ID: 29661268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies.
    Rawat P; Sehar U; Bisht J; Selman A; Culberson J; Reddy PH
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies.
    Moore KBE; Hung TJ; Fortin JS
    Drug Discov Today; 2023 Mar; 28(3):103487. PubMed ID: 36634842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of tau-induced neurodegeneration.
    Iqbal K; Liu F; Gong CX; Alonso Adel C; Grundke-Iqbal I
    Acta Neuropathol; 2009 Jul; 118(1):53-69. PubMed ID: 19184068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why Microtubules Should Be Considered as One of the Supplementary Targets for Designing Neurotherapeutics.
    Das G; Ghosh S
    ACS Chem Neurosci; 2019 Mar; 10(3):1118-1120. PubMed ID: 30657675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The central role of tau in Alzheimer's disease: From neurofibrillary tangle maturation to the induction of cell death.
    Thal DR; Tomé SO
    Brain Res Bull; 2022 Nov; 190():204-217. PubMed ID: 36244581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
    Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
    Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders.
    Kaur P; Khera A; Alajangi HK; Sharma A; Jaiswal PK; Singh G; Barnwal RP
    Mol Neurobiol; 2023 Mar; 60(3):1690-1720. PubMed ID: 36562884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tau pathology in Alzheimer disease and other tauopathies.
    Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening of treatment targets for Alzheimer's disease from the molecular mechanisms of impairment by β-amyloid aggregation and tau hyperphosphorylation.
    Lin LF; Luo HM
    Neurosci Bull; 2011 Feb; 27(1):53-60. PubMed ID: 21270904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau Proteins and Tauopathies in Alzheimer's Disease.
    Chong FP; Ng KY; Koh RY; Chye SM
    Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau Protein Interaction Partners and Their Roles in Alzheimer's Disease and Other Tauopathies.
    Sinsky J; Pichlerova K; Hanes J
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.
    Umeda T; Ono K; Sakai A; Yamashita M; Mizuguchi M; Klein WL; Yamada M; Mori H; Tomiyama T
    Brain; 2016 May; 139(Pt 5):1568-86. PubMed ID: 27020329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.
    Pradeepkiran JA; Reddy AP; Reddy PH
    Drug Discov Today; 2019 Feb; 24(2):616-623. PubMed ID: 30453058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
    Badiola N; Suárez-Calvet M; Lleó A
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.